Sales of ADDERALL XR for the six months to June 30, 2007 were $504.2 million, an increase of 18% compared to the same period in 2006 (2006: $426.8 million). Product sales growth was higher than prescription growth due primarily to a price increase in January 2007.
As previously disclosed, the United States Federal Trade Commission ("FTC") informed Shire on October 3, 2006 that it was reviewing the ADDERALL XR patent litigation settlement agreement between Shire and Barr Laboratories, Inc. ("Barr"). On June 22, 2007, Shire received a civil investigative demand requesting that it provide information to the FTC relating to its settlement with Barr and its earlier settlement with Impax Laboratories, Inc. Shire is cooperating fully with this investigation and believes that the settlements are in compliance with all applicable laws.
VYVANSE was launched in the US in June 2007. Launch stocks of $55.9 million (before sales deductions) were shipped to wholesalers during June 2007. In accordance with IFRS, sales of these launch stocks have been deferred pending satisfaction of revenue recognition criteria. All launch stocks are expected to be recognized into revenue by the end of 2007.
Following its launch in June 2006, DAYTRANA achieved an average market share during the six months to June 30, 2007 of 2%. Net sales for the six months to June 30, 2007 were $31.8 million.
The DAYTRANA and ADDERALL XR market share has helped Shire grow its total share of the US ADHD market to 28% at June 30, 2007 compared to 27% at June 30, 2006 (which included a 1% share relating to ADDERALL which Shire has subsequently divested).
PENTASA's average share of the US oral mesalamine prescription market
remained stable at 17% for the six months to June 30, 2007 compared to the
|SOURCE Shire plc|
Copyright©2007 PR Newswire.
All rights reserved